References
- FDA/Center for Drug Evaluation and Research. Eloxatin information. www.fda.gov/cder/drug/infopage/eloxatin/default.htm. Last updated: January 16, 2004. Accessed on March 1, 2005.
- Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303
- Shord SS, Bernard SA, Lindley C, Blodgett A, Mehta V, Chuechel MA, et al. Oxaliplatin biotransformation and pharmacokinetics: A pilot study to determine the possible relationship to neurotoxicity. Anticancer Res 2002; 22: 2301–9
- Kollmannsberger C, Rick O, Derings HG, Schleucher N, Schoffski P, Beyer, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ-cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20: 2031–7
- Machover D, Delmas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E, Schilf A, et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed no Hodgkin's lymphoma. Ann Oncol 2001; 12: 1439–43
- Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10: 4055–61